Stayble Therapeutics AB Balance Sheet

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1.1	2.45	2.2	14.08	12.85	37.47
Cash & Short-Term Investments	1.1	2.45	2.2	14.08	12.85	37.47
Cash Growth	-57.12%	11.70%	-84.41%	9.60%	-65.71%	244.77%
Other Receivables	0.41	0.23	0.13	0.25	0.61	0.45
Receivables	0.41	0.23	0.13	0.25	0.61	0.45
Prepaid Expenses	0.51	0.29	1.28	1.72	0.04	0.08
Total Current Assets	2.02	2.97	3.61	16.05	13.5	37.99
Long-Term Investments	-	-	-	-	-	0
Long-Term Deferred Charges	1.3	5.65	5.65	5.65	5.65	5.65
Total Assets	3.32	8.62	9.26	21.7	19.15	43.64
Accounts Payable	0.44	0.23	0.27	2.55	1.04	0.43
Accrued Expenses	0.39	0.36	1.07	1.56	1.82	2.2
Other Current Liabilities	0.58	0.26	0.2	0.23	0.15	0.35
Total Current Liabilities	1.41	0.85	1.53	4.34	3.02	2.98
Long-Term Debt	-	0.85	0.85	0.85	0.85	0.85
Other Long-Term Liabilities	0.85	-	-	-	-	-
Total Liabilities	2.26	1.7	2.38	5.19	3.87	3.83
Common Stock	8.37	8.37	5.68	4.12	1.8	1.8
Additional Paid-In Capital	-	3.56	-	-	36.08	48.18
Retained Earnings	-9.23	-6.93	-0.73	10.46	-24.53	-12.09
Comprehensive Income & Other	1.92	1.92	1.92	1.92	1.92	1.92
Shareholders' Equity	1.06	6.92	6.87	16.51	15.28	39.81
Total Liabilities & Equity	3.32	8.62	9.26	21.7	19.15	43.64
Total Debt	-	0.85	0.85	0.85	0.85	0.85
Net Cash (Debt)	1.1	1.6	1.35	13.23	12	36.62
Net Cash Growth	-35.93%	19.09%	-89.83%	10.28%	-67.24%	272.78%
Net Cash Per Share	-	0.03	0.04	0.51	0.87	2.64
Filing Date Shares Outstanding	-	64.36	51.72	31.72	13.85	13.85
Total Common Shares Outstanding	-	64.36	43.72	31.72	13.85	13.85
Working Capital	0.61	2.12	2.07	11.71	10.48	35.01
Book Value Per Share	-	0.11	0.16	0.52	1.10	2.87
Tangible Book Value	1.06	6.92	6.87	16.51	15.28	39.81
Tangible Book Value Per Share	-	0.11	0.16	0.52	1.10	2.87